-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBX-102 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBX-102 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EBX-102 in Acute Myelocytic Leukemia (AML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBX-102 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBX-102 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EBX-102 in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBX-102 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBX-102 in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EBX-102 in Myelodysplastic Syndrome Drug Details: EBX-102 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBX-102 in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBX-102 in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EBX-102 in Chronic Myelomonocytic Leukemia (CMML) Drug Details: EBX-102...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin SSD in Hepatic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifaximin SSD in Hepatic Encephalopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin SSD in Hepatic Encephalopathy Drug Details: Rifaximin soluble solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifamycin Sodium CR in Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifamycin Sodium CR in Bacterial Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifamycin Sodium CR in Bacterial Infections Drug Details: Rifamycin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rifaximin SSD in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rifaximin SSD in Sickle Cell Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rifaximin SSD in Sickle Cell Disease Drug Details: Rifaximin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBX-102 in Irritable Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBX-102 in Irritable Bowel Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EBX-102 in Irritable Bowel Syndrome Drug Details: EBX-102 is under...
-
Company Insights
NewGenfit SA Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Genfit SA Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Genfit SA (Genfit) is a late-stage biopharmaceutical company. It develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include VS-01-ACLF, nitazoxanide (NTZ), inhibitor SRT-015, CLM-022, VS-02-HE, GNS561, VS-01-HAC, TS-01 and NIS2+. Genfit's products are used in various therapeutic areas including acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea...
-
Product Insights
Likelihood of Approval Analysis for Hepatic Encephalopathy
Overview How likely is it that the drugs in Hepatic Encephalopathy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hepatic Encephalopathy Overview Hepatic encephalopathy is a worsening of brain function that...